Public Health
Volume 123, Issue 8 , Pages 523-533 , August 2009

Effect of privatization of the drug distribution system on drug prices in Malaysia

  • Z.D. Babar

      Affiliations

    • School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85, Park Road, Grafton, Auckland, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64 9 373 7599x88436; fax: +64 9 3677192.
    • ,
  • M.I.M. Izham

      Affiliations

    • Universiti Sains Malaysia, Penang 11800, Malaysia

Received 20 June 2008 ,Revised 6 May 2009 ,Accepted 21 June 2009.

References 

  1. Sangaralingam M, Raman M. The high cost of private monopolies, original report. 2003;Malaysia. Available at: www.sowatch.org.uy/en/informmesNacionales/351.html[accessed 10.01.05]
  2. Shepard SD, Savedoff W, Hong PK. Healthcare reform initiatives in Malaysia. Report of a consultation with the planning and development division. Kuala Lumpur: Ministry of Health; 2002;Available at: http://www.who.int/health_financing/countries/en/malaysia.pdf
  3. In:  Velden KVD,  Ginneken JKSV,  Velema JP,  de Walle FB,  Winjen JHV editor. Health matters: public health in north–south perspective. Amsterdam: Royal Tropical Institute; 1995;p. 43–62
  4. World Health Organization . World Health Report. Working together for health. Geneva: WHO; 2006;
  5. In:  Quick JD,  Rankin JR,  Laing RO,  O'Connor RW,  Hogerzeil HV,  Dukes MN, et al. editor. Managing drug supply. 2nd ed.. West Hartford, CT: Kumarian Press; 1997;
  6. Lek CS. Health plan to be modeled after Sosco. The Star. 14/12/2005;
  7. Lyles A. Medical spending increases, but pharmaceuticals pose a paradox. Clin Ther. 2002;24:300–301
  8. Babar ZU, Ibrahim M, Izham M, Bukhari NI. Effect of privatization of drug distribution system on the prices of anti-infectives in Malaysia. J Pharm Finan Econ Pol. 2004;13:3–26
  9. Devaraj K. Healthcare privatization will burden Malaysia. Aliran Month. 2004;24:
  10. Babar ZU, Ibrahim M, Izham M, Bukhari NI. A pricing analysis of cardiovascular and blood products after privatization of dug distribution system in Malaysia. J Pharm Finan Econ Pol. 2005;14:
  11. Farmasi B. Cost of drugs, Editorial. 1981.
  12. Consumer Association of Penang. Consumer Association of Penang memorandum on drug prices in Malaysia – the need for control. Malaysia; 1994.
  13. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:e82
  14. Ministry of Health . Drug prices in Malaysia. Press Release; 1996;
  15. National Medicine Policy . National medicine policy draft 7. Malaysia: Pharmaceutical Services Division, Ministry of Health; 2003;Available at: www.crc.gov.my/nmus/documents/draf%207%20NMP%20already%20presented%20to%20mesy%20khas%20kpk.pdf
  16. Lek CS. More than a politician. Med Grapevine. 2005;7–8
  17. In:  McFadyen JE editors. International drug price indicator guide 2003. Boston: Management Sciences for Health; 2004;
  18. Gilman AG, Hardman JG, Limbird LE. Goodman and Gilman's pharmacological basis of therapeutics. 10th ed.. New York: McGraw Hill; 2001;
  19. Essential drug list. WHO Model List 13th ed.. Department of Essential Drug and Medicine Policy; 2003;
  20. The national health morbidity survey. Malaysia: Ministry of Health; 1996;
  21. Division of Burden of Disease Institute for Public Health . Malaysian burden of disease and injury study. In: Health prioritization: burden of disease approach. Malaysia: Ministry of Health; 2004;
  22. In:  Sarojini S,  Lim TO editor. Malaysian statistics on medicine 2004. 2006;Kuala Lumpur. Available at: www.crc.gov.my/nmus
  23. Babar ZU, Izham M, Ibrahim M, Bukhari NI. Medicine utilization and pricing: the findings of a household survey in Malaysia. J Gene Med. 2005;3:47–61
  24. International Study of Asthma and Allergies in Chilldhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998;12:315–335
  25. Rugayah B. Report on second national health and morbidity survey. Public Health Institute, Ministry of Health; 1997;p. 94–8
  26. Lim TO, Ding LM, Zaki M, Suleiman AB, et al. Distribution of blood glucose in a national sample of Malaysian adults. Med J Malaysia. 2000;55:65–77
  27. Clifton JA. Administered prices in the context of capitalist development. Contrib Polit Econ. 1985;4:
  28. Sarmiento AZ. Alternate drug pricing policies in the Americas. Health economics and drugs. Geneva: World Health Organization; 1995;DAP Series No.1. WHO/DAP/95.6
  29. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability: an international comparison of chronic disease medicines. Cairo: World Health Organization/Health Action International; 2006;Available at: http://mednet3.who.int/medprices/CHRONIC.pdf
  30. Tripathi SK, Dey D, Hazra A. Medicine prices and availability in the state of West Bengal, India. 2004;Available at: http://www.haiweb.org/medicineprices/surveys/200412IW/survey_report.pdf
  31. Kotwani A. Medicine prices in the state of Rajasthan, India. 2004;Available at: http://www.haiweb.org/medicineprices/surveys.php
  32. Wickremasinghe R. Evidence, policy and advocacy workshop on medicine prices. Kandy: World Health Organization and Health Action International; 2006;
  33. Piong J. Post conference session on pharmacy education. In: Proc. MPS Pharmacy Scientific Conference, Kuala Lumpur; 13 November 2005.
  34. Export markets another growth source for domestic pharmaceuticals. The Star. 2003;
  35. Balasubramaniam K. Policies and strategies on drug pricing, regulations and international experience. Penang: International Organization of Consumers Union, Regional Office for Asia and the Pacific; 1988;
  36. Vandergrift M, Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy. 1997;41:241–260
  37. What price competitiveness in the drug industry?. Lancet. 2003;362:257
  38. Ng LK. The law of medicinal drug regulating safety, efficacy, quality and pricing. LL.B. thesis. Kuala Lumpur: University of Malaya; 1994. p. 119.
  39. Azmi IM, Alavi R. TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J World Intellect Prop. 2001;4:
  40. Mahmood M, Bukhari NI. Pharmaceutical management and marketing. Faisalabad: Tariq Academy; 2002;p.115–44
  41. Vogel JR. Pharmaceutical patents and price controls. Clin Ther. 2002;24:
  42. Carey J, Barrett A. Drug prices: what's fair. Bus Week. 10/12/2001;Available at: http://www.businessweek.com/magazine/content/01_50/b3761001.htm
  43. An innovative challenge to the pharmaceutical industry. Lancet. 2002;360:
  44. Pecoul B, Chirac P, Trouillern P, Pinel J. Access to essential drugs in poor countries: a lost battle. JAMA. 1999;28:
  45. Lopert R, Lang DL, Hill SR, Henry DA. Differential pricing of drugs: a role for cost-effectiveness analysis. Lancet. 2002;359:
  46. Pharmaceutical Price Regulation Scheme . Seventh report to parliament. Department of Health; 2003;
  47. Pharmaceutical price regulation scheme. Discussion paper. Available at: http://www.dh.gov.uk/assetRoot/04/06/73/32/04067332.PDF2003;
  48. Darshni S. Medicine prices being sold at high prices. New Strait Times. 09/05/2006;
  49. Babar ZU, Izham M, Ibrahim M, Harpal S, Bukhari NI. A survey of medicine prices, availability, affordability and price components in Malaysia using the WHO/HAI methodology. UCSI-USM; 2005;Available at: http://www.haiweb.org/medicineprices/surveys/200410MY/survey_report.pdf
  50. Awang C, Zin C. Access to medicine still good. New Strait Times. 26/01/2006;
  51. Razak AD. Curing the high-cost syndrome. New Strait Times. 11/07/2006;Available at: http://202.144.202.76/new_mps/cfm/localnews_view.cfm?id=874[accessed 12.07.06]

PII: S0033-3506(09)00168-1

doi: 10.1016/j.puhe.2009.06.011

Public Health
Volume 123, Issue 8 , Pages 523-533 , August 2009

Article Tools

* Image Usage & Resolution